SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
MENLO PARK, Calif., Feb. 15, 2018 -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its 2017 financial results and provide a corporate update on
February 22, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-800-289-0459 from the United States or 1-323-794-2558 internationally approximately 10 minutes before the start of the call. The passcode is 094798.
A replay will be available through March 8, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 1581123.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym is the company’s first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
[email protected]
www.corcept.com
